Benjamin T Ristau1, Denise S O'Keefe2, Dean J Bacich1. 1. Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA. 2. Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA. Electronic address: okeeds@upmc.edu.
Abstract
OBJECTIVE: Despite a multitude of detection and treatment advances in the past 2 decades, prostate cancer remains the second leading cause of deaths due to cancer among men in the United States. Technological evolution and expanding knowledge of tumor biomarkers have invigorated exploration in prostate cancer therapeutics. Prostate-specific membrane antigen (PSMA) was one of the first prostate cancer biomarkers successfully cloned. Since then, it has been characterized as the prototypical cell-surface marker for prostate cancer and has been the subject of intense clinical inquiry. In this article, we review the relevant research in PSMA on the 20th anniversary of its cloning. METHODS AND MATERIALS: A PubMed search using the keywords "prostate-specific membrane antigen" or "glutamate carboxypeptidase II" provided 1019 results. An additional 3 abstracts were included from scientific meetings. Articles were vetted by title and abstract with emphasis placed on those with clinically relevant findings. RESULTS: Sixty articles were selected for inclusion. PSMA was discovered and cloned in 1993. Its structure and function were further delineated in the ensuing decade. Consensus sites of expression in normal physiology are prostate, kidney, nervous system, and small intestine. PSMA has been implicated in the neovasculature of several tumors including urothelial and renal cell carcinomas. In prostate cancer, expression of PSMA is directly related to the Gleason grade. PSMA has been tested both in imaging and therapeutics in a number of prostate cancer clinical trials. Several recent approaches to target PSMA include the use of small molecule inhibitors, PSMA-based immunotherapy, RNA aptamer conjugates, and PSMA-targeted prodrug therapy. Future study of PSMA in prostate cancer might focus on its intracellular functions and possible role in tumor neurogenesis. CONCLUSIONS: Twenty years from its discovery, PSMA represents a viable biomarker and treatment target in prostate cancer. Research to delineate its precise role in prostate carcinogenesis and within the therapeutic armamentarium for patients with prostate cancer remains encouraging.
OBJECTIVE: Despite a multitude of detection and treatment advances in the past 2 decades, prostate cancer remains the second leading cause of deaths due to cancer among men in the United States. Technological evolution and expanding knowledge of tumor biomarkers have invigorated exploration in prostate cancer therapeutics. Prostate-specific membrane antigen (PSMA) was one of the first prostate cancer biomarkers successfully cloned. Since then, it has been characterized as the prototypical cell-surface marker for prostate cancer and has been the subject of intense clinical inquiry. In this article, we review the relevant research in PSMA on the 20th anniversary of its cloning. METHODS AND MATERIALS: A PubMed search using the keywords "prostate-specific membrane antigen" or "glutamate carboxypeptidase II" provided 1019 results. An additional 3 abstracts were included from scientific meetings. Articles were vetted by title and abstract with emphasis placed on those with clinically relevant findings. RESULTS: Sixty articles were selected for inclusion. PSMA was discovered and cloned in 1993. Its structure and function were further delineated in the ensuing decade. Consensus sites of expression in normal physiology are prostate, kidney, nervous system, and small intestine. PSMA has been implicated in the neovasculature of several tumors including urothelial and renal cell carcinomas. In prostate cancer, expression of PSMA is directly related to the Gleason grade. PSMA has been tested both in imaging and therapeutics in a number of prostate cancer clinical trials. Several recent approaches to target PSMA include the use of small molecule inhibitors, PSMA-based immunotherapy, RNA aptamer conjugates, and PSMA-targeted prodrug therapy. Future study of PSMA in prostate cancer might focus on its intracellular functions and possible role in tumor neurogenesis. CONCLUSIONS: Twenty years from its discovery, PSMA represents a viable biomarker and treatment target in prostate cancer. Research to delineate its precise role in prostate carcinogenesis and within the therapeutic armamentarium for patients with prostate cancer remains encouraging.
Authors: P M Smith-Jones; S Vallabahajosula; S J Goldsmith; V Navarro; C J Hunter; D Bastidas; N H Bander Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701
Authors: P Sácha; J Zámecník; C Barinka; K Hlouchová; A Vícha; P Mlcochová; I Hilgert; T Eckschlager; J Konvalinka Journal: Neuroscience Date: 2006-12-05 Impact factor: 3.590
Authors: Susan F Slovin; Marissa Kehoe; Robert Durso; Celina Fernandez; William Olson; Jian P Gao; Robert Israel; Howard I Scher; Stephen Morris Journal: Vaccine Date: 2012-12-13 Impact factor: 3.641
Authors: Gustavo E Ayala; Hong Dai; Michael Powell; Rile Li; Yi Ding; Thomas M Wheeler; David Shine; Dov Kadmon; Timothy Thompson; Brian J Miles; Michael M Ittmann; David Rowley Journal: Clin Cancer Res Date: 2008-12-01 Impact factor: 12.531
Authors: Michael S Cookson; Bruce J Roth; Philipp Dahm; Christine Engstrom; Stephen J Freedland; Maha Hussain; Daniel W Lin; William T Lowrance; Mohammad Hassan Murad; William K Oh; David F Penson; Adam S Kibel Journal: J Urol Date: 2013-05-09 Impact factor: 7.450
Authors: Catharina M van Rij; Cathelijne Frielink; David M Goldenberg; Robert M Sharkey; Gerben M Franssen; Susanne Lütje; William J McBride; Wim J G Oyen; Otto C Boerman Journal: Mol Imaging Biol Date: 2015-02 Impact factor: 3.488
Authors: Shiv Ram Krishn; Amrita Singh; Nicholas Bowler; Alexander N Duffy; Andrea Friedman; Carmine Fedele; Senem Kurtoglu; Sushil K Tripathi; Kerith Wang; Adam Hawkins; Aejaz Sayeed; Chirayu P Goswami; Madhukar L Thakur; Renato V Iozzo; Stephen C Peiper; William K Kelly; Lucia R Languino Journal: Matrix Biol Date: 2018-08-08 Impact factor: 11.583
Authors: Amarnath Mukherjee; Binod Kumar; Koji Hatano; Luisa M Russell; Bruce J Trock; Peter C Searson; Alan K Meeker; Martin G Pomper; Shawn E Lupold Journal: Mol Cancer Ther Date: 2016-08-02 Impact factor: 6.261
Authors: Patty Wong; Lin Li; Junie Chea; Melissa K Delgado; Erasmus Poku; Barbara Szpikowska; Nicole Bowles; Megan Minnix; David Colcher; Jeffrey Y C Wong; John E Shively; Paul J Yazaki Journal: Cancer Biother Radiopharm Date: 2017-09 Impact factor: 3.099
Authors: Reshani H Perera; Al de Leon; Xinning Wang; Yu Wang; Gopal Ramamurthy; Pubudu Peiris; Eric Abenojar; James P Basilion; Agata A Exner Journal: Nanomedicine Date: 2020-04-26 Impact factor: 5.307
Authors: James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher Journal: Neurochem Res Date: 2019-11-20 Impact factor: 3.996
Authors: Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter Journal: Am J Nucl Med Mol Imaging Date: 2020-12-15
Authors: Michael A Gorin; Steven P Rowe; Jody E Hooper; Max Kates; Hans-Joerg Hammers; Zsolt Szabo; Martin G Pomper; Mohamad E Allaf Journal: Eur Urol Date: 2016-06-28 Impact factor: 20.096